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ABSTRACT
Objective Early results of a randomised trial showed
reduced ﬁbrosis due to recurrent HCV hepatitis with
tacrolimus triple therapy (TT) versus monotherapy (MT)
following transplantation for HCV cirrhosis. We evaluated
the clinical outcomes after a median 8 years of follow-
up, including differences in ﬁbrosis assessed by collagen
proportionate area (CPA).
Design 103 consecutive liver transplant recipients with
HCV cirrhosis receiving cadaveric grafts were randomised
to tacrolimus MT (n=54) or TT (n=49) with daily
tacrolimus (0.1 mg/kg divided dose), azathioprine
(1 mg/kg) and prednisolone (20 mg), the last tailing off
to zero by 6 months. Both groups had serial transjugular
biopsies with hepatic venous pressure gradient (HVPG)
measurement. Time to reach Ishak stage 4 was the
predetermined endpoint. CPA was measured in all
biopsies. Factors associated with HCV recurrence were
evaluated. Clinical decompensation was the ﬁrst
occurrence of ascites/hydrothorax, variceal bleeding or
encephalopathy.
Results No signiﬁcant preoperative, peri-operative or
postoperative differences between groups were found.
During 96 months median follow-up, stage 4 ﬁbrosis
was reached in 19 MT/11 TT with slower ﬁbrosis
progression in TT (p=0.009). CPA at last biopsy was
12% in MT and 8% in TT patients (p=0.004). 14 MT/
three TT patients reached HVPG≥10 mm Hg (p=0.002);
10 MT/three TT patients, decompensated. Multivariately,
allocated MT (p=0.047, OR 3.23, 95% CI 1.01 to 10.3)
was independently associated with decompensation: 14
MT/ seven TT died, and ﬁve MT/ four TT were
retransplanted.
Conclusions Long term immunosuppression with
tacrolimus, azathioprine and short term prednisolone in
HCV cirrhosis recipients resulted in slower progression to
severe ﬁbrosis assessed by Ishak stage and CPA, less
portal hypertension and decompensation, compared with
tacrolimus alone.
ISRCTN94834276—Randomised study for
immunosuppression regimen in liver transplantation.
INTRODUCTION
We published early results of a randomised trial in
liver transplant recipients with HCV cirrhosis asses-
sing tacrolimus monotherapy (MT) versus tacroli-
mus, azathioprine and prednisolone triple therapy
(TT), which showed a slower onset of histological
severe ﬁbrosis and portal hypertension in the TT
arm compared with tacrolimus alone, independent
of other factors known to affect ﬁbrosis.1 This was
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Signiﬁcance of this study
What is already known on this subject?
▸ Immunosuppression worsens severity of
recurrence of HCV after liver transplantation.
▸ There are very few studies and only one
randomised study assessing immunosuppressive
protocols on different severity of recurrence of
chronic HCV hepatitis.
What are the new ﬁndings?
▸ Triple therapy with tacrolimus, azathioprine and
tapering steroids resulted in less ﬁbrosis
progression compared with tacrolimus
monotherapy, contrary to the initial hypothesis,
that less immunosuppression should reduce
progression of HCV recurrent disease.
▸ Triple therapy also resulted in less progression
of clinically signiﬁcant portal hypertension
(hepatic venous pressure gradient ≥10 mm Hg)
and less clinical decompensating events
(ascites, bleeding, varices, encephalopathy).
▸ Discontinuation of azathioprine resulted in
further ﬁbrosis progression compared with
continuation of azathioprine.
▸ The ﬁbrosis progression with triple therapy is
the lowest recorded in the literature.
How might it impact on clinical practice in
the foreseeable future?
▸ This trial obliges a review of
immunosuppressive protocols in patients
transplanted with HCV cirrhosis. The use of
azathioprine should be considered.
▸ Azathioprine and other immunosuppressive
agents need to be tested in HCV replicon
systems to assess if there is a direct antiviral
effect and in cell systems for any potential
immunological interaction with proﬁbrotic and
antiﬁbrotic mechanisms.
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contrary to the starting hypothesis that the lesser immunopo-
tency with MT should result in less ﬁbrosis.
However, despite our initial trial results and other consistent
data with more patients,2–4 including a possible beneﬁt with
azathioprine,5 the optimal immunosuppression for HCV trans-
plant recipients is still debated.6 Indeed, immunosuppression
worsens the severity of HCV recurrence.6 Cyclosporine has no
advantage versus tacrolimus regarding stage progression7 despite
in vitro (but not in vivo) activity against HCV.8 Tacrolimus com-
pared with cyclosporine improves both patient and graft survival
including patients transplanted for hepatitis C cirrhosis6 and is
the preferred calcineurin inhibitor.
Therefore, we evaluated outcomes in our trial, after a median
of 8 years of follow-up, including the original end points as well
as differences in hepatic venous pressure gradient (HVPG) and
collagen proportionate area (CPA) as a quantitative measure of
ﬁbrosis and clinical decompensation.
PATIENTS AND METHODS
Inclusion—exclusion criteria, randomisation and endpoints
From January 2000 to June 2007, at the Royal Free Hospital,
consecutive transplant recipients were randomised if they had
cirrhosis, were HCV RNA positive in serum and previous hist-
ology was compatible with HCV liver disease. Randomisation at
the Royal Edinburgh Inﬁrmary and St Vincent’s University
Hospital was between 12/2003 and 5/2006. Inclusion and exclu-
sion criteria were published previously.1 The study protocol was
approved by the Hospital Ethics committees at each site.
Follow-up stopped at death, retransplantation or 1/2013. We
analysed the original primary endpoints—progression to Ishak
stage 4 and graft failure either resulting in retransplantation or
patient’s death. We also evaluated patients’ survival, acute cellular
rejection episodes, chronic rejection, recurrence of HCV (deﬁned
by Ishak inﬂammation score≥4), HVPG progression to 10 mmHg,
CPA, ﬁbrosis progression assessed by CPA and Ishak stage (for
comparison with other published studies), and time to ﬁrst episode
of clinical decompensation deﬁned as whichever occurred ﬁrst, of
ascites/hydrothorax, variceal bleeding or encephalopathy.
For each patient, the following were evaluated: demographic
and clinical data (including concomitant hepatocellular carcin-
oma (HCC) and/or alcoholic aetiology), donor age/gender, cold/
warm ischaemia time, initial immunosuppression and subse-
quent changes, occurrence and treatment of rejection episodes,
cytomegalovirus or other infections, histological episodes of de
novo hepatitis, genotype, viral load pre-LT and 1 year post-liver
transplantation (LT), antiviral treatment and sustained viro-
logical response (SVR), diabetes mellitus pretransplant and post-
transplant, human leucocyte antigen and blood group compati-
bility of donor/recipient, sex match/mismatch and tacrolimus
levels at 5, 15 and 30 days post-LT.
Immunosuppression regimens
The MT group received tacrolimus 0.1 mg/kg/day (two divided
doses). The TT group received the same tacrolimus dosing,
together with azathioprine—initially intravenously then orally—
1 mg/kg/day, and methylprednisolone (16 mg/day intravenous)
until oral intake was established (20 mg/day prednisolone).
Tacrolimus trough concentrations were evaluated on alternate
week days. The doses were adjusted to maintain a whole blood
level within 5–14 ng/mL (aiming for 5–10). Azathioprine was
continued at the same starting dose unless neutropenia devel-
oped: 16 patients discontinued azathioprine between 10 and
37 months (median 14 months) post-LT. Prednisolone was grad-
ually tapered from 3 weeks onwards and then stopped between
3 and 6 months, according to each centre’s practice. Protocol
biopsies were undertaken to diagnose acute cellular rejection
between days 5 and 10. If moderate or severe rejection was
diagnosed, daily intravenous 1 gm methylprednisolone was
given for 3 days.9
Virological assays
Determination of HCV genotype was performed by reverse
transcription PCR and reverse hybridisation assay of the ampli-
ﬁed sequence (InnoLipa HCV II, Innogenetics, Zwijnaarde,
Belgium).10
Qualitative tests were performed by a reverse transcription
PCR assay (Amplicor HCV, Roche Diagnostic Systems Inc,
Branchburg, New Jersey, USA—later Bayer Thermomechanical
Analyzer Component system, Berkeley, California, USA).11
Liver biopsies
Protocol liver biopsies were performed at yearly intervals and
also if clinically indicated. All liver biopsies were reviewed by
liver trained histopathologists in each centre, in a blinded
fashion.
Liver biopsy samples were formalin ﬁxed, parafﬁn embedded
and stained with H&E, Gordon and Sweet staining was used
for reticulin and Sirius red and Van Gieson stains were used in
Edinburgh. All biopsies at the Royal Free Hospital were
restained with picroSirius Red to ensure comparable staining for
collagen quantiﬁcation and determination of CPA by digital
image analysis. The stage of disease (ﬁbrosis 0–6) and the grade
of necroinﬂammatory activity were evaluated according to Ishak
et al.12
The number of liver cores, length of biopsy (lengths of each
core summed), and portal tract number per core and in total
were recorded.13 Liver biopsies<12 mm long were excluded (29
of 310). Complete portal tracts were deﬁned according to
Crawford and colleagues.14 The equipment used and CPA meas-
urement were performed as previously described.15
Acute cellular rejection was graded using the Royal Free
Hospital score.16 Histological de novo hepatitis (HDNH) C
termed ‘histological acute hepatitis C’ previously1 2 was deﬁned
as before as an increase in alanine aminotransferase levels (>2
upper normal limit), together with histological changes consist-
ent with hepatitis without diagnostic features of cellular rejec-
tion, duct loss or other cause of liver injury, including
alloimmune hepatitis (autoantibodies negative).2
Fibrosis progression in each patient was calculated by percent-
age change of ﬁbrosis according to CPA (CPA in latest biopsy
subtracted from CPA at 1 year post-LT, divided by time in years
between the two biopsies: CPA%/year). Ishak stage progression
was calculated as in latest biopsy subtracted from stage in the
biopsy at 1 year, divided by time in years—stage ‘units’/year
between the two biopsies.
Statistical analysis
Results are expressed as median and ranges. Categorical vari-
ables were compared using the χ2 or Fisher’s exact tests.
Continuous variables were compared by Student t test, or if not
normally distributed by the Mann–Whitney test. We compared
the two randomised groups for histological, virological and clin-
ical outcomes in a preplanned evaluation.
Statistical comparison was made by life tables (Kaplan–Meier)
and log rank testing. All the following variables associated with
HCV recurrence in the literature (table 1)—except IL28B—were
evaluated in the Cox regression analysis: donor age/gender, cold/
warm ischaemia time, initial and changes in immunosuppression
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occurrence and treatment of rejection episodes, cytomegalovirus
or other infection, HDNH episodes, genotype, viral load pre-LT
and 1 year post-LT, antiviral treatment and SVR, diabetes mellitus
pre-LT and post-LT, human leucocyte antigen and blood group
compatibility of donor/recipient, sex match/mismatch and tacroli-
mus levels at 5/15/30 days post-LT.
A p value<0.05 was considered statistically signiﬁcant. SPSS
V.20.0 was used.
Patients were censored at the time of SVR, when analysing
progression to HVPG≥10 mm Hg, to CPA cut-offs of 6% and
7.2%, to ﬁrst clinical decompensation event, and survival. As
reported previously, sample size was calculated to be 110
patients: S4 was estimated to occur in 35% by 3 years with a
projected decrease to 10% with tacrolimus MT, and this
required a sample size of 99. Considering a dropout rate of
10% (including early deaths), we concluded that 110 patients
would be needed with a two-tailed test with signiﬁcance at 5%
and a power of 80% (1-B).17
RESULTS
Patients’ demographic and transplant data
A total of 103 patients (89 Royal Free Hospital, eight Royal
Edinburgh Inﬁrmary and six St Vincent’s Hospital) were rando-
mised as previously documented:1 29 women, 74 men; 30 had
HCC and 22 concomitant alcoholic liver injury. In the last
follow-up, there were only two alcohol relapsers, one in each
randomised arm. Two patients were coinfected with hepatitis B
or D virus (remained HBV–DNA negative in blood throughout
the study).
By randomisation, 54 received MT and 49 TT. The groups
were well matched at randomisation with no signiﬁcant differ-
ences in preoperative, peri-operative or immediately post-
operative variables: four were retransplanted early post-LT, two
for hepatic artery thrombosis and one for primary non-function
in the MT group; and one TT for hepatic artery thrombosis.
Two MT patients were withdrawn within the ﬁrst month
post-LT because of side effects of treatment.
We analysed the remaining 97: 49 MT and 48 TT. Median
follow-up was 96 months (range 1–146): 91.6 months MT and
98.7 months TT; 15/97 (15.5%) died within 3 years from ran-
domisation. In all, 78/97 (80%) had a follow-up of more than
3 years, fulﬁlling the sample size calculation based on Log rank
testing.
Clinical characteristics were well balanced and HCV geno-
types were similarly distributed. In tacrolimus MT: 20 patients
genotype 1 (41%), seven genotype 2 (14%), 16 genotype 3
(33%) and six genotype 4 (12%). In TT group, the distribution
was 20 patients genotype 1 (41%), one genotype 2 (2%), 19
genotype 3 (40%), seven genotype 4 (15%) and genotype 5 (2%).
Median HCV RNA levels were not signiﬁcantly different, pre-
transplant or at 1 or 3 months post-LT.1 Antiviral treatment for
HCV recurrence was used in 25 of 30 patients reaching stage 4
(19 MT, 11 TT), with six achieving SVR (18, 36 and 52 months
MT; 36, 38 and 40 months TT). The median time to initiate
therapy was the same in the two trial arms: 45 months for 19
MT patients and 51 months for 11 TT patients. All patients
were treated with pegylated interferon α-2b 0.5 μg/kg weekly
escalating to 1 μg/kg, and ribavirin 200 mg escalating to
Table 1 Variables evaluated in the univariate analysis for the different endpoints examined
Stage 4
MT TT p Value CPA≥6% CPA≥7.2% HVPG≥10 mm Hg Decompensation
Cold/warm ischaemia time (min) 680/46 688/41 NS NS NS NS NS
Treatment allocation (evaluated) 54 (49) 49 (48) <0.001 <0.001 <0.001 <0.001 <0.001
Stopped azathioprine NA 16 (33%) <0.001 <0.001 <0.001 0.012 0.013
Tacrolimus trough concentrations (ng/mL)
5 days 7.7 5 0.002 0.002 0.01 0.017 0.01
15 days* 8.5 6.1 0.003 0.001 0.01 0.001 0.01
30 days* 7.9 6.7 0.01 0.01 0.04 0.02 0.01
Conc. HCC 17 13 NS NS NS NS 0.03
Conc. ALD 10 12 NS NS NS NS NS
Age 48.9 years 50 years NS NS NS NS NS
Donor age 48.5 years 44 years 0.01 0.01 0.01 0.04 0.02
Gender mismatch 17 17 NS NS NS NS NS
Rejection episodes 42 64 0.002 0.0033 0.04 0.033 NS
Rejection treatment (courses) 21 30 0.002 0.01 0.03 0.038 NS
HDNH 17 8 <0.001 <0.001 <0.001 <0.001 <0.001
CMV viraemia treated 7 10 NS NS NS NS NS
Viral load logIU/mL (median)
Pre-LT 5.29 5.36 NS NS NS NS NS
3 m post-LT 6.6 6.39 NS NS NS NS NS
Genotype 1/1b 41% 41% NS NS NS NS NS
Antiviral treatment 19 11 0.01 0.01 0.01 0.001 0.001
SVR 3 3 NS NA NA NA NA
DM
Pre-LT 13 13 NS NS NS NS NS
Post-LT (last follow-up) 19 15 0.013 0.038 0.044 NS NS
*Median trough levels derived from all measurements up to days 15 and 30 post-LT.
ALD, alcoholic liver disease; CMV, cytomegalovirus; CPA, collagen proportionate area; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HDNH, histological de novo hepatitis;
HVPG, hepatic venous pressure gradient; LT, liver transplantation; MT, monotherapy; NA, non-applicable; NS, non-significant; SVR, sustained virological response; TT, triple therapy.
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800 mg/daily. The HDNH episodes were only diagnosed within
6 months post-LT, and occurred in 17 MT and eight TT
patients.
Tacrolimus trough levels were a median of 7.7 ng/mL (MT)
and 5 ng/mL (TT) (p=0.03) at 5 days; 8.5 ng/mL (MT) and
6.1 ng/mL (TT) (p=0.017) at 15 days post-LT; and 7.9 ng/mL
(MT) and 6.7 ng/mL (TT) (p=0.031) at 30 days post-LT. The
difference in median tacrolimus levels was maintained up to
6 months post-LT: 7 ng/mL in MT group versus 5.8 ng/mL in
TT arm (p=0.044). There was no difference at 1 year post-LT.
The median tacrolimus levels at 1 year post-LTwere not signiﬁ-
cantly different between those who discontinued azathioprine
before 1 year post-LT (7.7 ng/mL) versus those who were still on
azathioprine at that point (6.7 ng/mL).
There were no new rejection episodes compared with those
previously published:1 9 During the ﬁrst 3 months, 22 MT had
42 rejection episodes and 16 received 21 courses of methylpred-
nisolone. In comparison, 31 TT had 64 rejection episodes and
24 received 30 courses of methylprednisolone. It should be
noted that after the last bolus, steroid dosage (if in TT arm)
reverted to 20 mg/day (ie, no high to low tail off of oral ster-
oids) or none in MTarm.
The proportion of patients whose serum creatine rose
to≥130 mmol/L (1.5 mg/dL) during the ﬁrst 3 months post-
transplant was similar: 23% MT versus 20% TT. At the last
follow-up, abnormal serum creatine (>1.5 mg/dL) was noted in
nine out of 37 (24%) patients alive in the MTand ﬁve out of 41
(12%) patients alive in TT group. No patient has ended up on
dialysis. Incidence of diabetes post-LT was 33% MT and 31%
TT.
There was no difference in numbers of biopsies and average
number of biopsies/patient performed between groups. Patients’
characteristics are shown in table 2. The number of patients
with suitable biopsies evaluated for Ishak staging was 90/97
(45 MT/45 TT) and for CPA was 81/89 Royal Free patients
(37 MT/44 TT).
Factors associated with reaching Ishak stage 4 or greater
At least stage 4 was reached by 19 MT patients at a median of
32 months: eight reached stage 4, eight stage 5 and three stage
6. Correspondingly, 11 TT patients reached stage 4 or greater at
a median of 49 months (six reached stage 5, none stage 6).
Patients receiving antiviral treatment or achieving SVR were not
censored as treatment in all patients was initiated after reaching
Ishak stage 4 or greater. In univariate and multivariate analyses,
three factors were associated with ﬁbrosis stage ≥4: randomisa-
tion to allocated MT treatment (p=0.001, OR 2.94, 95% CI
1.3 to 6.7), HDNH (p=0.015, OR 2.67, 95% CI 1.23 to 5.8)
and discontinuation of azathioprine (p=0.036, OR 2.24, 95%
CI 1.3 to 3.9). Patients who died without reaching stage 4 (four
MT, one TT) were censored at the last biopsy with its Ishak
stage. Hazard curves of MT/TT allocation (p=0.005 Mantel–
Cox) and use/discontinuation of azathioprine (p=0.003
Mantel–Cox) are shown in ﬁgure 1.
Factors associated with CPA cut-offs
As previously published, CPA of 6% at 1 year biopsy post-LT
was highly predictive of clinical outcome in a larger recurrent
HCV population after liver transplantation3 and CPA of 7.2%
was independently associated with portal hypertension, that is,
HVPG ≥6 mm Hg.15 We used the cut-off of 6% of CPA and the
time to ﬁrst reach CPA≥6% to compare the allocated treat-
ments, including a multivariate analysis: 20 MT patients
reached CPA≥6% (20/37 or 54%) at a median of 41 months,
while 13 TT reached CPA≥6% (13/44, 30%) at a median of
49 months. In the multivariate analysis, allocated treatment with
MT (p=0.007, OR 2.67, 95% CI 1.31 to 5.46) and HDNH
(p=0.001, OR 3.27, 95% CI 1.61 to 6.6) were independently
associated with CPA≥6%. For CPA≥7.2%, allocated MT treat-
ment (p=0.004, OR 2.85, 95% CI 1.38 to 5.86), HDNH
(p=0.006, OR 2.69, 95% CI 1.32 to 5.48) and discontinuation
of azathioprine (p=0.011, OR 2.1, 95% CI 1.1 to 2.8) were
independent factors. Hazard curves are shown in ﬁgure 2 for
CPA cut-offs of 6% and 7.2% (p=0.002 and p=0.001 Mantel–
Cox respectively).
Factors associated with portal hypertension
HVPG measurement was performed combined with transjugular
biopsies in 33 MT and 31 TT patients. These represent 78%
MT and 72% TT patients surviving at 1 year at the Royal Free
Hospital as HVPG was not measured in Edinburgh or Dublin.
There were 154 HVPG measurements post-LT: 64 at a median
of 17 months, 41 at a median of 31 m, 30 at a median of 48 m,
15 at a median of 63 m and four at a median of 86 m.
HVPG≥10 mm Hg (clinically signiﬁcant portal hypertension)
was reached in 11 MT compared with four TT patients. Cox
regression analysis revealed HDNH (p=0.015, OR 3.68, 95%
CI 1.26 to 10.69) and allocated MT treatment (p=0.017, OR
4.13, 95% CI 1.28 to 13.29) to be independently associated
with HVPG≥10 mm Hg: hazard curves are shown in ﬁgure 3
(p=0.027 Mantel–Cox and 0.019 Breslow).
Table 2 Characteristics of patients transplanted for HCV cirrhosis
randomised to either tacrolimus monotherapy or triple therapy
(tacrolimus, prednisolone and azathioprine)
Monotherapy
49
Triple therapy
48
Follow-up (median)
96 (1–146) m 91.6 98.7
Biopsies performed
Years 1/2 34/27 40/30
Years 3/4 26/17 27/19
Years 5/6 18/14 16/13
Years 7/8 11/9 10/9
Years 9/10 2/3 2/2
Biopsy index* 3.31 3.48
Reaching Ishak stage 4
N 19 11
Median 32 m 49 m
Reaching CPA≥6%
N 20/33 (61%) 13/39 (33%)
Median 41 m 49 m
Reaching CPA≥7.2%
N 21/33 14/39
Median 42 m 51 m
Reaching HVPG≥10 mm Hg
N 11/33 4/31
Decompensated
n (months) 9 (70 months) 4 (91 months)
Deaths
n 14 7
*Biopsy index per patient (months of follow-up divided by the number of biopsies
from 1 year onwards).
CPA, collagen proportionate area; HVPG, hepatic venous pressure gradient.
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Factors associated with clinical decompensation
Decompensation occurred in 13 patients (all reached stage 5/6
at the time of decompensation) at a mean of 82 months: nine
MT patients (seven ascites, one variceal bleeding, one encephal-
opathy) at a mean of 70 m and four TT patients (three ascites,
one encephalopathy) at a mean time of 91 m. Hazard curves are
shown in ﬁgure 3 (p=0.015 by Mantel–Cox, 0.037 Breslow).
In the Cox regression analysis, allocated MT treatment was
the only statistically signiﬁcant factor associated with clinical
decompensation (p=0.047, OR 3.23, 95% CI 1.01 to 10.3).
Fibrosis progression rate
We evaluated 310 biopsies for Ishak stage and 289 biopsies for
CPA due to inadequate material for restaining. The number of
biopsies performed every year were: 74 in year 1 (34 MT/40
TT), 57 in year 2 (27 MT/30 TT), 53 in year 3 (26 MT/27 TT),
36 in year 4 (17 MT/19 TT), 34 in year 5, (18 MT/16 TT), 27
in year 6 (14 MT/13 TT), 21 in year 7 (11 MT/10 TT), 18 in
year 8 (9 MT/9 TT), 4 in year 9 (2 MT/2 TT) and 5 in year 10
(3 MT/2 TT). Fibrosis progression according to CPA and stage
progression over time are shown in ﬁgure 4. Median CPA ﬁbro-
sis progression rate was 0.7%/year (0.74%/year MT, 0.67%/year
TT). Mean stages per year (given for comparison with published
studies) were: at 1 year (1.45), 2 years (2.1), 3 years (2.38),
4 years (2.86), 5 years (3), 6 years (3.2), 7 years (3.2) 8 years
(3.47), 9 years (4) and 10 years (5). Mean stages for MT group
were: 1.58, 2.37, 2.77, 3.18, 3.28, 3.66, 3.22, 4, 5 and 5, and
for TT group were: 1.3, 1.9, 2, 2.57, 2.6, 2.77, 3, 2.87, 3 and
3 for years 1–10 post-LT respectively. Mean Ishak stage progres-
sion rate was 0.2 stage U/year (0.3 stage U/year in MT, 0.2 stage
U/year TT).
Fibrosis progression rate was not signiﬁcantly different
between patients requiring steroids boluses for acute cellular
rejection or not. Median CPA ﬁbrosis progression rate was
0.72%/year in those requiring steroids boluses and 0.69%/year
in those not treated for acute cellular rejection. Mean Ishak
stage progression rate was 0.2 stage U/year in both groups.
Factors associated with early survival overall survival
and graft survival
In the TT group three patients died within 3 months: one
patient after retransplant (sepsis—2 days) and two at 1 month
from sepsis and multiple organ failure. There were another four
deaths: one due to non-liver related causes at 6 months, two
from recurrent HCV disease (30 and 42 months) and one at
95 months from recurrent HCC.
In the MT group, 14 patients died: ﬁve from sepsis and mul-
tiple organ failure (0.3, 0.3, 0.6, 1 and 4 months), one from
graft failure (0.5 months), one from pulmonary hypertension
(0.2 months), one from ductopenic rejection (18 months) and
one from recurrent HCV disease (30 months). Six more patients
died in the current update: three from recurrent HCV disease
(36, 37 and 72 months post-LT), one from embolic stroke
(56 months) and one from lung adenocarcinoma (96 months).
Overall, mortality in the randomised 103 patients favoured
TT patients (p=0.036) as well as the 97 currently evaluated
(p=0.025). However, there was no statistically signiﬁcant factor
associated with mortality in the multivariate analysis, and no sig-
niﬁcant difference in deaths due to HCV recurrence.
Similarly, graft survival favoured the TT arm (p=0.019): 15
MTand seven TT patients died, and ﬁve MT/4 TTwere retrans-
planted, but this difference was not due to recurrent disease.
Figure 1 Hazard curves of Ishak stage 4. Hazard curves of reaching Ishak stage 4 in the two treatment arms (p=0.005 Mantel–Cox). In all, 19 MT
patients reached stage ≥4 at a median of 32 months, while 11 TT reached stage ≥4 at a median of 49 months post-LT. Sixteen patients
discontinued azathioprine between 10 and 37 months post-LT. MT, monotherapy; TT, triple therapy.
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DISCUSSION
In this ﬁnal evaluation of our randomised study,1 the median
follow-up was just over 8 years, the longest published to date
following liver transplantation in a randomised trial concerning
HCV cirrhosis,6 18 and given the numbers who either died
within 3 years or survived more than 3 years (used for sample
size calculation), this allowed a robust evaluation of clinical out-
comes of recurrent HCV disease. Our outcomes included ﬁrst
clinical decompensation event (evaluated for the ﬁrst time),
HVPG and ﬁbrosis progression deﬁned by CPA and Ishak stage.
Fibrosis progression after liver transplantation for hepatitis C
related cirrhosis has been studied several times19–24 mainly by
assessing changes in Ishak/Metavir scores. Fibrosis progression is
well recognised to have prognostic signiﬁcance before25 and
after transplantation.4 The overall rate of increase of disease
stage described by changes in Ishak staging in our total trial
population is similar or lower than ﬁbrosis rates previously
described.22–24 The mean ﬁbrosis Ishak stage was 1.45 and 2.1
in years 1 and 2 post-LT in our whole cohort, and 1.3 and 1.9
at years 1 and 2 post-LT respectively for the TT group, which
are as low as those recently published in patients receiving siroli-
mus (which may have antiﬁbrotic properties) compared with
historical controls (0.62 and 1.15 metavir in year 1 and 2 biop-
sies, respectively).26
Figure 2 Hazard curves of collagen proportionate area (CPA) 6% and 7.2%. Hazard curves of reaching CPA 6% and 7.2% with those achieving
sustained virological response censored (18 m MT, 36 m TT, 36 m MT, 38 m TT, 40 m TT, 52 m MT) in the two treatment arms (p=0.002 for CPA
6% and p=0.001 for CPA 7.2% by Mantel–Cox). Sixteen patients discontinued azathioprine between 10 and 37 months post-LT. MT, monotherapy;
TT, triple therapy.
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The relatively low overall rate of increase of disease stage in
our trial population most likely reﬂects use of combined therapy
of tacrolimus with azathioprine and steroids and/or the gener-
ally lower trough levels of tacrolimus achieved.2 Since our ﬁrst
publication, we have shown that CPA assessment in HCV
post-LT patients correlates with both Ishak stage scores and
HVPG, with greater percentage changes in CPA, compared with
HVPG in early portal hypertension.15 Moreover, CPA at 1 year
biopsy post-LT is highly predictive of clinical outcome in HCV
transplanted patients and better than Ishak stage or HVPG.3 In
the current update, MT and HDNH were independently asso-
ciated with reaching CPA cut-offs of 6%3 and 7.2%, the latter
corresponding to HVPG≥6 mm Hg,15 reinforcing both the
value of CPA and validating these cut-offs as endpoints.27
As in our ﬁrst publication,1 outcomes favouring the TT group
are supported by HVPG measurements.28 There was more clin-
ically signiﬁcant portal hypertension (associated with advent of
complications and worse survival)29 in the MT group (11
patients reached HVPG≥10 mm Hg, compared with four TT)
corroborating the more severe ﬁbrosis found in MT patients.
The signiﬁcance of HDNH is again conﬁrmed by us1 2 4 and
others30 as this was independently associated with Ishak stage 4,
but also CPA cut-offs for decompensation and HVPG.
A limitation in this study could be the lack of evaluation of
recipient IL28B polymorphism, which was also missing in the
recent sirolimus study.26 Some studies suggest a higher recur-
rence rate of HCV hepatitis with the poor interferon response
allele of IL28B in the recipient.31 32 However, randomisation
will most likely have balanced out the more favourable poly-
morphism, which in any case is under represented in liver trans-
plant populations.32 Moreover, IL28B was not signiﬁcantly
associated with either overall or liver related mortality in one
study,32 and there has been a selection bias in most studies, as
only patients with biopsies were evaluated, that is, not every
patient with recurrent hepatitis C was biopsied.31 Moreover, no
study evaluated immunosuppression when analysing severity of
recurrence.31–35 Last, some studies do not show an association
of recipient IL28B with worse HCV disease recurrence.36
Our TT group received azathioprine, which many centres
have substituted with mycophenalate which however may
worsen ﬁbrosis progression compared with azathioprine.5 In
addition, low dose maintenance steroids may also favour less
severe recurrence and improve graft survival.37–39 However, the
use of steroids in transplantation for HCV cirrhosis remains an
unresolved issue.6 Interestingly, although steroids boluses greatly
increase HCV RNA levels,40 our TT group had more rejection
episodes treated with high dose steroids,9 so it may be that the
long term beneﬁt of immune modulation with steroids is more
important than the risk of HCV activation following steroid
boluses for rejection. Indeed, a recent study has shown no dis-
tinct advantage of steroid avoidance18 and another group have
shown that steroid-free immunosuppression leads to a higher
rate of chronic rejection.41
In conclusion, long term maintenance immunosuppression
with tacrolimus, azathioprine and shorter term prednisolone in
HCV cirrhosis recipients resulted in a slower onset of histo-
logical severe ﬁbrosis conﬁrmed by Ishak stage and CPA, less
portal hypertension, and less clinical decompensation compared
with tacrolimus alone. Our results support and extend our
initial report.1 Given that our TT arm has the lowest ﬁbrosis
progression rate published so far—lower than sirolimus—26 and
that there is some evidence that azathioprine is better than
Figure 3 (A) Hazard curves of developing hepatic venous pressure gradient (HVPG)≥10 mm Hg and clinical decompensation. Hazard curves of
developing HVPG≥10 mm Hg in the two treatment arms (p=0.019 by Breslow) in 33 MT and 31 TT. In all, 11 MT reached HVPG≥10 mm Hg,
compared with four TT. Patients achieving sustained virological response (SVR) before reaching HVPG≥10 mm Hg were censored at the time of SVR.
(B) Hazard curves of decompensation, deﬁned as whichever occurred ﬁrst of ascites/hydrothorax, variceal bleeding or encephalopathy, in our trial
cohort (p=0.037 by Breslow). Decompensation occurred in 13 patients: nine MT at a mean of 70 m and four TT at a mean time of 91 m. Patients
achieving SVR were censored at the time of SVR. MT, monotherapy; TT, triple therapy.
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mycophenalate,5 our TT regimen could be considered as a ﬁrst
choice for patients transplanted for HCV cirrhosis, until other
evidence proves otherwise.
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